Work

Improved glycemic and weight control with Dulaglutide addition in SGLT2 inhibitor treated obese type 2 diabetic patients at high cardiovascular risk in a real-world setting. The AWARE−2 study

Year: 2024

Type: article

Study design: Observational Study

Abstract: ; p<0.0001). Efficacy of Dulaglutide was not affected by different CVD risk categories, age and T2DM duration. This real world study provides evidence for significant reductions in HbA1c level, body mass index and body weight in obese type 2 diabetic patients who received add-on treatment with the weekly GLP-1RA, Dulaglutide.

Source: Pharmacological Research

DOI: 10.1016/j.phrs.2024.107517

Authors: Cesare Berra, Roberto Manfrini, Francesco Bifari, Elisa Cipponeri, Renata Ghelardi, Lucia Centofanti, Umberto Mortola, Elena Lunati, Loredana Bucciarelli, Vincenzo Cimino, Franco Folli

Institutions: MultiMedica, University of Milan, Ospedale San Paolo, Azienda Socio Sanitaria Territoriale Santi Paolo e Carlo, ASST Melegnano e della Martesana, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital

Language: English

Topic: Diabetes Treatment and Management

Subfield: Endocrinology, Diabetes and Metabolism

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,740

Funder: Ministero della Salute

OpenAlex ID: W4404813356

FWCI: 4.59

Cites: 74

Cited by: 17

Related to: 10